{"url_path":"/sec/cnta/8-k/2026-06-24/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","accession_number":"0001193125-26-280337","cik":"0001847903","ticker":"CNTA","issuer_name":"Centessa Pharmaceuticals plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","primary_entity_key":"0001847903","primary_entity_name":"Centessa Pharmaceuticals plc"},"word_count":151,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit Number\n  \n\nDescription of Exhibit\n\n2.1\n  \n[Transaction Agreement, dated as of March 31, 2026, by and among Lilly, Purchaser and the Company (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed on March 31, 2026 (SEC File No. 001-40445).*](http://www.sec.gov/Archives/edgar/data/1847903/000119312526134656/d145970dex21.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nSchedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally to the U.S. Securities and Exchange Commission a copy of any omitted schedule or exhibit upon request.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 24, 2026\n\n \n\nCENTESSA PHARMACEUTICALS PLC\n\nBy:\n \n\n/s/ Kristina Mignon Wright\n\nName:\n \nKristina Mignon Wright\n\nTitle:\n \nDirector"}